Search results
Results from the WOW.Com Content Network
Volume growth of Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature ...
For premium support please call: 800-290-4726 more ways to reach us
Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), is a United States Supreme Court case in which the Court held that Amgen's two patent applications on cholesterol-lowering drugs failed to satisfy the enablement clause of §112 of the Patent Act, 35 U.S.C. § 112(a).
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
For premium support please call: 800-290-4726 more ways to reach us
In 2023, the company reported $6.7 billion in profit on $28.2 billion in sales. Amgen's debt should come down A big concern for investors today is Amgen's debt.
For premium support please call: 800-290-4726 more ways to reach us
Top Research Reports for Amazon, Amgen & TOTAL